1. Home
  2. Browse
  3. HRA010385
HRA010385
   HRA010385.xlsx
Title:
Integrating multi-omics platforms for panoramic identification of therapeutic tumor vaccines
Release date:
2025-02-22
Description:
Through the collection of tumor samples for WES and RNA-Seq sequencing and third-generation sequencing technology (Oxford Nanopore, ONT), we can conduct a panoramic, multi-omics integrated analysis of clinical tumor data such as somatic variations (including SNVs, INDELs, Fusions, Alternativate splicing), HLA typing (HLA I, II), and gene transcript expression to predict and screen potential tumor neoantigens with high confidence. We provide panoramic, integrated multi-omics analysis of clinical tumor data, including SNVs, INDELs, Fusions, Alternativate splicing, HLA typing (HLA I, II), and gene transcript expression, to predict and screen potential tumor neoantigens with high confidence.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA035950
Study type:
Disease Study
Disease name:
acute myeloid leukemia
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC005463
DAC name:
Shengyue Wang Research Group
Contact person:
Wang Shengyue
Email:
wsy12115@rjh.com.cn
Description:
Including experts and scholars from Dr. Shengyue Wang's research team
Individuals & samples
Files
Request Data
Submitter:   Wang Shengyue / wsy12115@rjh.com.cn
Organization:   Ruijin Hospital, Shanghai jiaotong University School of Medicine
Submission date:   2025-02-10
Requests:   -